Semax / Selank
Semax, an ACTH-fragment peptide approved in Russia for post-stroke cognitive recovery, is paired here with Selank, a related peptide studied for anxiety and mental fatigue — together targeting cognitive clarity and stress resilience.
- Semax approved in Russia for post-stroke cognitive recovery
- Selank studied for anxiolytic and antiasthenic effects
- Combines cognitive and stress-resilience research
No commitment · Cancel anytime · Physician evaluation required
About Semax / Selank
Semax and Selank are synthetic heptapeptides sharing a stabilizing structural motif, developed by Russian researchers from different parent hormones — Semax from ACTH, Selank from tuftsin (an immune-signaling peptide). Semax is approved as a medicine in Russia for cognitive impairment following ischemic stroke; Selank has been studied there for generalized anxiety and neurasthenia (a fatigue-and-stress condition).
What the research shows — and its limits
Both peptides have a real regulatory foothold in Russia, unlike many wellness-market peptides, and Semax specifically has been studied for effects on BDNF (brain-derived neurotrophic factor) levels and stroke recovery outcomes. However, a 2026 comparative review notes that the bulk of Semax and Selank clinical evidence originates from a small number of Russian research institutions, much of it published in Russian-language journals and not independently replicated in Western randomized controlled trials. Available human imaging studies (small fMRI studies of brain connectivity) are mechanistic and exploratory rather than clinical efficacy trials.
Regulatory note
Semax is among the peptides currently under FDA Pharmacy Compounding Advisory Committee review as of mid-2026.
Who it's for
This combination is often considered by adults interested in cognitive clarity and stress resilience, with a clear-eyed understanding that most of the supporting research hasn't been independently replicated outside the originating research groups.
How It's Administered
Both peptides are commonly administered via subcutaneous injection or intranasal delivery. Your physician will determine an appropriate protocol during your evaluation.
Safety & Considerations
Available data from Russian clinical use has not identified significant safety concerns for either compound, but neither has the large-scale, independently-replicated controlled trial base of an FDA-approved medication.
Your physician will review your health history during your evaluation. Not all applicants will qualify.
Selected References
The following peer-reviewed sources informed the summary above. Evidence quality varies — some reflect large controlled human trials, others early-stage or animal research, as noted.
- Semax vs Selank: Benefits, Mechanisms & Safety Compared
Clinical research summary, 2026 - Compare Semax, Selank & DSIP — evidence base and regional research concentration summary
NewGen Peptides research guide, 2026